ArticleCureus2026
Incidence and Radiological Spectrum of Interstitial Lung Disease in Patients With Lung Cancer Treated With Tyrosine Kinase Inhibitors: A Single-Center Observational Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Tyrosine kinase inhibitors (TKIs) have improved outcomes in driver mutation-positive non-small cell lung cancer (NSCLC), yet drug-induced interstitial lung disease (ILD) remains an uncommon but clinically relevant toxicity. Objectives To determine the incidence and radiological spectrum of ILD among lung cancer patients receiving TKIs, describe accompanying adverse effects, identify clinical and treatment-related risk factors, and estimate progression-free survival (PFS). Methods This single-center observational study included consecutive mutation-positive lung cancer patients treated with TKIs between January 2024 and September 2025 at a tertiary institute in Eastern India. Baseline demographic, clinical, radiological, and molecular data were recorded. Patients were followed for 12 months with structured clinical assessment, laboratory monitoring, and imaging. ILD was classified as TKI-attributable or all-cause. Results Among 106 patients, most were aged 50 years or older (80.2%), male participants (54.7%), non-smokers (85.8%), and had advanced-stage disease (93.4%). Epidermal Growth Factor Receptor (EGFR) exon19 (50.9%) and exon21 (16.0%) mutations dominated in the group. Erlotinib (48.1%) and osimertinib (22.6%) were most frequently used. TKI-induced ILD occurred in 3.7% of patients, while all-cause ILD occurred in 16.0%. Radiologically, 95.3% of the study group showed no ILD pattern. Disease control was achieved in 68.8% of cases. Mean PFS was 10.4 ± 2.91 months, with a 12-month survival of 61.2%. Mild toxicities predominated; 84.0% had no Common Terminology Criteria for Adverse Events (CTCAE)-graded toxicity at one year. Smoking status correlated with treatment response (p=0.045), and Eastern Cooperative Oncology Group (ECOG) performance predicted PFS (p=0.048). No baseline factor independently predicted ILD. Conclusions TKIs demonstrated favorable disease control with low attributable ILD. Continued monitoring and structured risk assessment remain essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.